Abstract: The purpose of this study was to evaluate the DDM as a carrier of recombinant human BMP-2 (rhBMP-2). In the study 1, the rhBMP-2 was fixed to inorganic bovine bones, tricalcium phosphate (TCP), DDM powder, and DDM chip. Over a period of 36 days, the amount of rhBMP-2 released was analyzed. In the study 2, the expression of protein markers by rhBMP-2 combined with DDM was evaluated in mice at 1, 2 and 4 weeks. In the control group (n=20 mice), 20 μg grafts of TCP+rhBMP-2 (concentration=0.05 mg/ml) were applied, while in the experimental group (n=20 mice), 20 μg grafts of DDM powder+rhBMP-2 (concentration=0.05 mg/ml) were applied. In the study 1, the slow release of rhBMP-2 was exhibited by all four graft types throughout the 36-day, a statistically significant large amount of rhBMP-2 was released from the DDM powder compared to the other materials (p<0.05). In the study 2, the expression of osteonectin was found to be limited to adjacent areas of TCP in the control group, however, it was observed in the DDM in the experimental group. The experimental group exhibited significant mature bone formation in the 4th week, but not in the 1st week of the experiment. Within limited research in this study DDM powder appears to have great potential as an effective scaffold for rhBMP-2. In the DDM powder+rhBMP-2, new bone formation was evidently shown and the amount of released rhBMP-2 was the highest. It was proposed that DDM powder might be an effective carrier of rhBMP-2.
Introduction
Various bone graft materials and surgical methods can be applied to regenerate the alveolar bone defects that can result from tooth or alveolar bone loss caused by periodontal disease, trauma, tumor, and tooth extraction, in order to enable functional and esthetic recovery. However, many of these graft materials lack osteoinductive potential (an exception being autogenous bone), despite possessing good biocompatibility and osteoconductive potential; their osteogenic potential is unsatisfactory. Much research has thus focused on graft materials mixed with additives, such as bone morphogenetic protein (BMP; a protein with osteoinductive potential) or fibroblast differentiation promoting factor, which may secure a material with excellent osteogenic potential 1, 2) . Since 1965, Urist first extracted BMP from decalcified bone matrix 3) , more than 20 types of osteoinductive protein have been discovered worldwide. BMP is a member of the transforming growth factor family that exists naturally in various body tissues. It induces the generation of undifferentiated mesenchymal cells in the defective bone region, and is thus involved in the production of cartilage and bone precursor cells. BMP ultimately contributes to the generation of new bone via endochondral ossification in parallel with completed differentiation into chondroblasts, osteoblasts, and osteocytes 4) . However, the application of BMP alone has certain limitations in that it is not well manipulated and does not persist in situ, which is due to it being rapidly resorbed in the graft region. Thus, it cannot continue to induce the generation of new bone. A scaffold is required to prevent the BMP form being resorbed so that it can induce osteogenesis over long periods. The requirements of such a scaffold are that it should be highly biocompatible and have zero toxicity, immunogenicity, and carcinogenicity. Moreover, it should be easy to produce without interrupting the osteoinductive effect of BMP, and should be able to work functionally as a bone graft material until it is resorbed during the course of normal bone remodeling, and disappears in vivo 5, 6) .
In 2008, an autogenous tooth bone graft material was developed from human extracted teeth, and subjected to many basic and clinical studies. It has since been found to be an excellent biocompatible material with osteoinductive and osteoconductive potential [7] [8] [9] [10] [11] [12] . It has microporous structures named dentinal tubules that could be loaded with bone growth factors such as BMP.
The purpose of this study was to evaluate the possible role of demineralized dentin matrix (DDM) as a scaffold for rhBMP-2. For the DDM powder, extracted human teeth were pulverized (0.5-1.0 mm) by removing the attached soft tissue. The pulp was removed, and sectioning was performed between the crown and the root. The ground tooth powder was washed to remove any adherent contaminants and remaining soft tissue. The washed powder was then dehydrated, defatted, and freeze-dried.
Materials and Methods
The DDM chips were made by first cutting extracted human teeth were at the cementoenamel junction, and then removing the soft tissues (including all endodontic soft tissue) and foreign substances that were attached to the tooth. A hole with a diameter of 0.2 mm was made 0.5-1.0 mm from the surface through the pulp chamber in each sample. The teeth were then washed using ethyl alcohol and decalcified for 2 hours in 0.6 N HCl by repeated 30-minute periods of water decalcification. The decalcified block was manufactured into a bone chip measuring 1.0-3.0 mm × 1.0 mm, then decalcified, defatted, and dewatered to reduce the mineral content to less than 5% by weight, leaving only type I collagen as the main constituent.
Fixation of rhBMP-2 (the dip-dry method)
The rhBMP-2 was fixed to the bone graft material by placing 2 mg/ml rhBMP-2 (Genoss, Suwon, Korea) and 0.03 g of each of the bone graft materials (i.e., Bio-Oss, TCP, DDM powder, or DDM chips) into individual 15-ml conical tubes. The mixtures were frozen in a deep freeze at -70 ºC, slotted into a lyophilization glass bottle, and then fixed in a lyophilizer (ILShin Lab, Seoul, Korea).
rhBMP-2 release kinetics in vitro
Fixed rhBMP-2 samples combined with Bio-Oss, TCP, DDM powder, and DDM chips were soaked in 1 ml of Dulbecco's phosphate-buffered saline in Eppendorf tubes and reacted at a 37ºC in a spinner culture machine. Over a period of 36 days, 1ml aliquots of the supernatant liquid were collected and replaced with fresh PBS. The amount of rhBMP-2 in the collected supernatant liquid was analyzed using the Lowry protein quantitative method of measuring the optical density with the aid of a UVspectrophotometer (Biochrome Libra S22, Cambridge, UK), and the potential effects of BMP were compared with reference to that of bovine serum albumin (Bioshop, Burlington, Canada).
Statistics
SPSS version 20.0 for Windows (SPSS, Chicago, IL, USA) was used to evaluate the data, using a paired t-test method. The level of statistical significance was set at p<0.05.
Study 2. Expression of protein markers by rhBMP-2 combined with DDM Animals
In this study, 40 nude mice weighing 15-20 g were used as experimental animals. These animals were bred with a free supply of cubed diet and water under average ambient temperature conditions of 22 ºC and a 12-hour shade cycle. The Institutional Animal Care and Use Committee approved this experiment.
Control and experimental groups
Two types of graft material were adopted as a scaffold for rhBMP-2 (CowellMedi): human DDM (Korea Tooth Bank) and TCP (CowellMedi). rhBMP-2-soaked TCP (TCP+rhBMP-2) was used for the control group (n=20), and rhBMP-2-soaked DDM (DDM+rhBMP-2) was used for the experimental group (n=20).
Methods

Scanning electron microscopy (SEM) analysis of the graft materials
SEM (S-4800, Hitachi, Tokyo, Japan) was used to observe the surface structure of the DDM+rhBMP-2 and TCP+rhBMP-2.
The surface of the specimens was coated with up to 7 nm of platinum before being observed at magnifications of ×5,000 and ×10,000.
Subcutaneous grafting
General anesthesia was induced in the mice by intra-abdominal injection of pentobarbital sodium (43 mg/kg; Nembutal, Dainabot, Tokyo, Japan). The operation field was isolated after disinfection.
Next, the dorsal portion of each mouse was incised to form a subcutaneous pouch on both sides. In the control group, 20-μg grafts of TCP+rhBMP-2 (concentration=0.05 mg/ml) were applied to the pouches, while in the experimental group, 20-μg grafts of DDM+rhBMP-2 (concentration=0.05 mg/ml) were applied. The wound was sutured closed with nylon after placement of the grafts. Antibiotic ointment was then applied to the sutured region to prevent postoperative infection.
Production and observation of tissue specimens
The mice in each group were sacrificed at 1, 2 and 4 weeks after the graft procedure, and tissue specimens (including the graft material and adjacent tissues) were harvested. The collected tissues were fixed in 10% buffered formalin for 10 days and then decalcified using formic acid, dehydrated using ethanol, and embedded in paraffin to produce samples. After staining with hematoxylin-eosin and Masson's trichrome, the tissues were observed with the aid of an optical light microscope (Olympus BX-51, Olympus Co., Tokyo, Japan) for histopathological analysis.
In addition, paraffin-embedded samples were deparaffinized by soaking in xylene solution for 30 minutes, and then hydrated in 100 %, 90 %, and 70 % ethyl alcohol. The samples were soaked in 3 % H 2 O 2 solution for 10 minutes to eliminate the endogenous peroxidase and enzymatically treated in 0.4 % trypsin solution for 20 minutes to expose the antigens. They were then reacted with horse serum (Vectastain kit, Vector, Burlingame, CA, USA) for 30 min and stained immunohistochemically using a primary antibody raised against osteonectin.
Quantitative analysis Evaluation of osteonectin expression in the dentinal tubules
The expression of osteonectin was evaluated by optical microscopy at a magnification of ×100. A digital camera installed on the microscope was used to obtain digital images, in which the number of osteonectin-expressing cells in the DDM grafts was counted within a defined area. The data are presented as the percentage of osteonectin-expressing cells compared to the total number of cells within an area of a predetermined size.
Evaluation of osteonectin expression in stromal cells
The expression of osteonectin in stromal cells per certain unit area was categorized into the following three levels based on the expression intensity and area: mild, 30 %; moderate, 60 %; and severe, 90 %.
Evaluation of new bone formation
New bone formation around the DDM was presented as the percentage of the total graft count per unit area.
Results
Study 1: Evaluation of bone graft materials as rhBMP-2 carriers in vitro
The burst release among the four types of bone graft materials was greatest for rhBMP-2 in DDM powder; the amounts of rhBMP-2 released by the remaining three graft types were similar to one another. In addition, although sustained and slow release of rhBMP-2 was exhibited by all four graft types throughout the 36-day experimental period (Fig. 1) , a statistically significantly larger amount of rhBMP-2 was released from the DDM powder compared to the other materials (p<0.05; Fig. 2 ). Of the materials tested, DDM may thus be the most appropriate rhBMP-2 vehicle for bone regeneration. 
SEM
According to SEM analysis, the dentinal tubule was well exposed in the dry DDM specimen (Fig. 3A) , but was shaded with liquid adsorbate in the DDM+rhBMP-2 specimen (Fig. 3B) . w e e k s a f t e r g r a f t i n g . Osteonectin was expressed mildly around the TCP, but was not expressed in the proliferated stromal cells in TCP+rhBMP-2 group (A, B). In the DDM+rhBMP-2 group (C, D), osteonectin was expressed in the dentinal tubules of the DDM (four stars). The DDM expressing osteonectin was surrounded by mature bone (Bone).
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In the case of TCP, there was no significant difference in shape between the dry specimen and the wet specimen on SEM examination (Fig. 3C, D) .
Histological examination
At 1 week after grafting, in the control group (TCP+rhBMP-2) the expression of osteonectin was found to be limited to adjacent areas of TCP, but was not observed in stromal cells. For the experimental group (DDM+rhBMP-2), the expression of osteonectin was found to be significant in the dentinal tubules but mild in the stromal cells.
At 2 weeks, in the control group the expression of osteonectin was found to be limited to adjacent areas of TCP (similar to the findings at 1 week); however, osteonectin expression was not observed in the stromal cells. In the experimental group, osteonectin remained strongly expressed in the dentinal tubules; stromal cells with mild osteonectin expression tended to gather around the graft. A mild degree of new bone formation was observed.
At 4 weeks, in the control group there was mild expression of osteonectin in the area adjacent to the TCP, but none was observed in the stromal cells. No mature bone formation was observed. In the experimental group the expression of osteonectin was still observed in the dentinal tubules and stromal cells, and lots of new bone had formed around the DDM (Fig. 4) .
Histomorphometric examination Evaluation of immunohistochemical osteonectin expression
1. Evaluation of relative osteonectin expression in the dentinal tubules (Table 1) The TCP+rhBMP-2 group exhibited no osteonectin expression (Table 2) The TCP+rhBMP-2 control group exhibited minimal osteonectin expression (less than 1 %) in the stromal cells during the experimental period, while the DDM+rhBMP-2 group exhibited static osteonectin expression. (Table 3) The DDM-rhBMP-2 group exhibited significant mature bone formation in the 4th week but not in the 1st week of the experiment.
Evaluation of relative new bone formation
Discussion
There have been many attempts to employ BMP clinically due to its established usefulness. Although many studies have focused on the extraction of BMP from human or animal bones or teeth, it could not be extracted in sufficient quantities for clinical application because of its trace content. However, recent advances in genetic engineering technology have now opened up opportunities to use mammalian cells or Escherichia coli (E. coli) to produce recombinant human BMP via genetic recombination [13] [14] [15] . rhBMP-2 was reported to facilitate the proliferation of osteoblasts from mesenchymal stem cells and contribute to the biosynthesis of bone matrix in the ultimate interest of new bone formation 16) . Nonetheless, BMP is highly soluble in nature, and so if used alone it dissolves too quickly before any significant osteoinductive effect can be generated. Many organic BMP delivery systems have been tested, such as collagen, calcium phosphates ( -TCP, hydroxyapatite, and TCP), polyesters (e.g., polycaprolactone), absorbable collagen sponge, demineralized bone matrix, and bovine deorganified crystalline bone matrix (BioOss) 17, 18) . However, these materials are of limited usefulness because they are rapidly resorbed, fail to maintain their volume for a long enough period, or fail to seed BMP in vivo.
A new delivery system, DDM, is known to contain many bone growth factors including type I collagen and BMP, and may thus be effective in osteoinductive and osteoconductive bone healing. Moreover, DDM is biocompatible and does not induce foreignbody reactions, rendering it a potentially good bone graft material in itself that may further function as an effective scaffold for BMP. 8) As part of the preliminary experiment for this study, rhBMP-2 was adsorbed onto graft materials by soaking (at concentrations of 50 ng/ml and 2 g/ml) for 30 min. Subsequent rhBMP-2 assays, and confocal laser scanning microscopy and SEM were conducted to compare the potential of DDM as a BMP carrier among various graft materials. Similar to the finding of Liu et al. 19) , almost none of the BMP adsorbed onto the graft material (Fig. 5) . This implies that contrary to general expectation, the BMP-soaked graft materials are unlikely to be clinically effective. Thus, in the study 1, the dip-dry method was adapted to seed rhBMP-2 to various bone graft materials, and the possible roles of these graft materials as scaffolds for BMP were evaluated.
The rhBMP-2 was found to seed better to DDM powder than to the other tested graft materials, thus demonstrating that DDM powder has superior characteristics as a BMP carrier. DDM powder contains both organic and inorganic components, whereas DDM chips have less mineral substances and consist mostly of type I collagen. Therefore, we tentatively concluded that DDM powder could work better as a scaffold than DDM chips and other bone graft materials. Bone-related genes (e.g., those encoding type I collagen, alkaline phosphatase, osteopontin, osteonectin, and osteocalcin) are consecutively expressed in the course of bone formation from the osteoblast proliferation phase, via the bone matrix formation phase, to the calcification phase. Thus, any protein expressed by genes at each phase can be used as markers to evaluate the osteogenic process [20] [21] [22] . In the present study, osteonectin, which is a secreted protein that is acidic and rich in cysteine (SPARC), was used as a marker to evaluate the osteoinductive potential of BMP. Th e t e r m " s c a ffo l d " r e fer s t o a g ra ft t h a t h el p s osteoproliferating cells to differentiate into calcifiable osteoblasts in a particular region; it is ultimately resorbed in vivo in the boneremodeling phase. 23) The existing synthetic bone grafts were limited as scaffolds, because they were unable to release the osteoactive substances reliably. On the other hand, DDM has dentinal tubules with diameters in the range 1.2-2.5 mm, and so may be viewed as a microporous structure that could be loaded with osteoinductive substances. These facts were the motivation behind this study.
In the study 2, the reliability of osteoinductive substance release from various graft materials was evaluated by soaking DDM and TCP in rhBMP-2 solution. It has been shown that decalcified dentin contains bone growth factors (like BMP) in combination with matrix; however, the minerals and cellular substances were removed in the present study with the exposure of the dentinal tubules, thus tending to expand its surface area 24, 25) .
Osteonectin was found within the dentinal tubules of the DDM+rhBMP-2 in this study, while no such findings were obtained for TCP+rhBMP-2, which has no porous structures. These findings suggest that DDM can contribute to the stable release of osteoinductive substances and function as a scaffold for bone formation.
Osteonectin is a matricellular protein that is expressed in tissues in which cell-matrix contact or intercellular contact is expected. It is also useful as a marker for the dynamic process of tissue variation, including fetal generation and tissue Young-Kyun Kim et al.: Demineralized Dentin Matrix Used as an rhBMP-2 Carrier modification 26) . Moreover, its SPARC characteristic, since it is secreted into tissues without any transmembrane domain, makes it acidic in tissues, and has relatively high amounts of cysteine. In bone tissues, osteonectin is known to be secreted from osteoblasts to begin calcification, promoting calcified crystallization 27) . Osteonectin is characterized by its expression at the time of inducing tissues to change, and is therefore a sensitive biochemical marker of osteogenesis before it becomes visible histologically.
In the present study, osteonectin was first expressed histologically as early as the 1st week after grafting. In DDM+rhBMP-2, osteonectin was expressed strongly in the dentinal tubules at an early stage, and its expression remained strong over the subsequent experimental period. On the other hand, the TCP used for the control group had no porous structure, and did not exhibit the expected effect of active material isolation seen with DDM+rhBMP-2.
DDM itself contains BMP within the dentinal tubules, even before soaking with BMP, since organic substances are not removed in the course of decalcification. Therefore, it was expected that osteonectin would be expressed effectively in the dentinal tubules. New bone formation was found to depend critically upon how stably the active substances can be isolated from the inside of dentinal tubules to the surrounding tissues. In this context, DDM can be considered a good graft material that can function well as a scaffold, since it can isolate active substances stably from the inside of its dentinal tubule. Based on the present finding of ectopic ossification in the soft tissues 4 weeks after grafting, it can be concluded that DDM is a good bone graft material that can stably release the BMP contained within it and function well as a scaffold, holding and stably isolating active substances that have been adsorbed onto it, such as BMP, over long periods.
